ICCGBS222221






TABLE OF CONTENTS

03 WELCOME MESSAGE

04 SCHEDULE

07 PRESENTERS

21 DIAMOND AND EMERALD SPONSORS

Welcome

CONTACT US

- +1 (909) 620-7214
- 🚩 info@gbs-intl.org
- 🈏 @GroupBStrep

O @GroupBStrep

Group B Strep International

💮 www.gbs-info.org

11 El Dorado Ct. Pomona, CA 91766 United States



Welcome to the International Conference on Group B Strep (ICGBS) 2021! This is our third ICGBS and we are excited for you to join this year's collaboration to reduce the burden of perinatal group B strep (GBS) disease worldwide.

About 1 in 4 pregnant women carry group B Streptococcus (GBS) which is a major cause of maternal and infant ill health worldwide. GBS can cause babies to be miscarried, stillborn, born premature, become very sick, have lifelong handicaps, and die after birth.

Thank you to our renowned keynote speaker, Professor Joy Lawn, and our outstanding presenters who have shared their expertise to make a difference for babies worldwide. We also want to recognize Hologic® as our Diamond Sponsor, our other corporate sponsors and our parent sponsors as well as the many individuals who support our efforts year-round for making this conference possible.

We hope you will enjoy learning from the experts, join the discussion on each presentation, and be inspired by the current research efforts posted on our Research Wall. Thank you for joining us in promoting healthier outcomes for babies worldwide!

MARTI PERHACH GBSI CEO AND COFOUNDER

Assav

Special thanks to our Diamond Sponsor HOLOGIC® PANTHER FUSION® GBS

TUESDAY SCHEDULE

JULY 20, 2021

KEYNOTE

20 million pregnant women with GBS worldwide: deaths, data on disability, and delivering change Joy Lawn, MB BS, MPH, PhD, FRCPCH, FMedSci

MATERNAL GBS COLONIZATION

Two Clinical Trials: The Efficacy of Probiotics to Reduce Antenatal GBS Lisa Hanson, PhD, CNM, FACNM, FAAN

The Efficacy of an Antenatal Probiotic Intervention to Reduce Residual Group B Streptococcus Emily Malloy, CNM, APNP, PhD Candidate

Smoking as a risk factor for group B streptococcal colonization during pregnancy Philip Kum-Nji, MD, MPH

The changing epidemiology of GBS urogenital infections: focus on diabetes and obesity Ryan Doster, MD, PhD

PATHWAYS OF GBS INFECTION

Impact of gestational diabetes on group B *Streptococcus* vaginal colonization and dissemination Kathryn A. Patras, PhD

Understanding the pathophysiology of GBS urinary tract infections in diabetes Ritwij Kulkarni, MSc, PhD

Group B *Streptococcus* β-hemolysin/cytolysin Modulates Intestinal Tight Junction Protein Gene Expression Kristen Domínguez, BA/BS

The Impact of GBS Virulence Factors on Pregnancy and Neonatal Outcomes Emily Huebner, MS

WEDNESDAY SCHEDULE

JULY 21, 2021

PREVENTION STRATEGIES

GBS Bacteriuria and Pregnancy Karen M. Puopolo, MD, PhD

Successful prevention of early preterm birth by pH-measurement as a self-care habit in the State of Thuringia: Aspects of the 2020 experience Udo Hoyme, Univ.-Prof. Dr. med. habil. Prof. Dr. h.c

Judith's stillbirth story and how her mother is affecting change in Canada to reduce preventable stillbirths through kicks counting Nadine Belzile, M.A.

The Use of Intramuscular Ceftriaxone in Infants during the First Week of Life to Minimize the Risk of Late Onset Group B Strep Disease in Inadequately, Prenatally Treated Newborns Robert A. Dracker, MD, MHA, MBA, CPI

Long Term Outcomes of GBS Meningitis Fatma Levent, MD

MANAGING PERINATAL LOSS

IMproving Perinatal Mortality Review and Outcomes Via Education Adrienne Gordon, MBChB, MRCP (UK), MPH (Hons), FRACP, PhD

ANTIMICROBIAL RESISTANCE AND GBS

Evolution of antimicrobial resistance in Group B streptococcus Elita Jauneikaite, BSc (Hons), PhD, MRSB

BREAST MILK AND GBS

Breast Milk and Group B Streptococcus Suzy Lim, PhD

THURSDAY SCHEDULE

JULY 22, 2021

NOVEL APPROACHES AND RESEARCH

Characterization of a novel GBS colonization factor Laura C. Cook, PhD

Investigating mechanisms of persistent Group B *Streptococcus* **colonization after intrapartum antibiotic prophylaxis treatment** Macy E. Pell, BS, PhD Candidate

Antibiotic adjuvants: rejuvenating our current arsenal of antimicrobials against Group B *Streptococcus* Sabrina K. Spicer, BS, current PhD student

Molecular characterization of invasive Group B streptococcus in South Africa, 2019-2020 Buhle Ntozini, BMedSci (Hons)

A mouse model reproducing the pathophysiology of neonatal group B streptococcal disease Elva Bonifácio Andrade, PhD

Commensal *Streptococcus salivarius* overcomes suppression of growth by pathogenic Group B *Streptococcus* Rebecca E. Moore, BS, MS

A type VII secretion system in Group B *Streptococcus* mediates cytotoxicity and virulence Brady Spencer, PhD

KEYNOTE SPEAKER:



JOY LAWN

MB BS, MPH, PhD, FRCPCH, FMedSci Professor of Maternal Reproductive and Child Health Epidemiology, Director of MARCH Centre, London School Hygiene & Tropical Medicine

Presentation: 20 million pregnant women with GBS worldwide: deaths, data on disability, and delivering change

Joy is an African-born, British-trained paediatrician and perinatal epidemiologist with 30 years' experience including: clinical care, epidemiological burden estimates, design and evaluation of maternal, newborn and child care services at scale, especially in sub-Saharan Africa. Her paediatric training was in the UK, followed by teaching, implementation and research, mainly living in Africa, including a decade with Save the Children. Her MPH was from Emory, Atlanta, USA, whilst at CDC, and her PhD at Institute of Child Health, London. For 10 years, she was Director of Evidence and Policy for Saving Newborn Lives/Save the Children and was mostly based in Africa.

She is currently Director of the MARCH Centre (Maternal Adolescent Reproductive & Child Health) at London School of Hygiene & Tropical Medicine, including more than 400 academics. Her main contribution to global health has been developing the evidence-base to measure and reduce the global burden of 2.5 million neonatal deaths, >2 million stillbirths, and 15 million preterm births, including informing the relevant Sustainable Development Goal target. She has published >280 peerreviewed papers including leading several influential Lancet series, with wide media and policy uptake. She and her research team work on multicountry studies on newborn health, stillbirths and child development worldwide, including NEST360 and novel work on Group B Streptococcus. She is a champion for research leadership, especially mentoring those from LMICS and women. She is one of the few women nominated to membership of both UK Academy of Medical Sciences and USA National Academy of Medicine.



NADINE BELZILE

M.A.

Presentation: Judith's stillbirth story and how her mother is affecting change in Canada to reduce preventable stillbirths through kicks counting

Nadine Belzile is a mom of 2 boys and a daughter she lost to stillbirth caused by GBS in 2012. She has an M.A. in social and cultural anthropology and has 15 years of experience as a public policy and research analyst for the Government of Canada. Last year, she founded BabyKicks.ca to raise awareness amongst pregnant women of the importance of fetal movement monitoring in the third trimester as a means to prevent stillbirth.



ELVA BONIFÁCIO ANDRADE

PhD

Presentation: A mouse model reproducing the pathophysiology of neonatal group B streptococcal disease

Elva Bonifácio Andrade has a degree in Biochemistry and a PhD in Biomedical Sciences obtained at Institute of Biomedical Sciences Abel Salazar, University of Porto. During her post-doctoral researcher, she has focused on the development of the first mouse model that recapitulates Group B Streptococcus (GBS) neonatal infection pathogenesis, with similar features to that described in humans. Now, she established a new line of research focused on the neuro-immune connections during GBS disease, aiming at developing new neuroprotective targets, with the potential to reduce the burden of neuropsychiatric morbidities in newborns and children.

LAURA C. COOK

PhD

Presentation: Characterization of a novel GBS colonization factor

Laura C. Cook is an Assistant Professor at SUNY Binghamton in New York. She earned her B.A. degree in English Literature and B.S. degree in Microbiology from the University of Minnesota in 2005. She has researched Gram-positive bacterial pathogens such as Staphylococcus aureus and pathogenic streptococci since 2003. After completing her PhD at the University of Minnesota in 2012, Dr. Cook begun her postdoctoral work at the University of Illinois in Chicago. In 2018, Dr. Cook moved to Binghamton University to begin a position as an Assistant Professor. Her lab focuses currently on two species of pathogenic streptococci, S. pyogenes and S. agalactiae and their interactions with host mucosal surfaces.



KRISTEN DOMÍNGUEZ

BA/BS

Presentation: Group B *Streptococcus* βhemolysin/cytolysin Modulates Intestinal Tight Junction Protein Gene Expression

Kristen Dominguez is a PhD student in Dr. Randis' lab co-mentored by Dr. Darch at the University of South Florida studying host-microbe interactions that facilitate GBS pathogenesis.



RYAN DOSTER

MD, PhD

Presentation: The changing epidemiology of GBS urogenital infections: focus on diabetes and obesity

Ryan Doster is an Assistant Professor of Clinical Medicine in the Division of Infectious Diseases at Vanderbilt University Medical Center. He earned a B.A. from Hanover College (Hanover IN) before attending Indiana University School of Medicine. Following completion of his medical degree, Dr. Doster completed a combined residency in Internal Medicine and Pediatrics at Indiana University School of Medicine. He then completed subspecialty training in adult infectious diseases medicine at Vanderbilt University Medical Center (Nashville TN). During his fellowship, Dr. Doster completed a Ph.D. in Microbe-Host Interactions, where his research focused on interactions between GBS and innate immune cells within the female reproductive tract. His current research program examines how host diet and nutrition might impact GBS vaginal colonization and perinatal infections.



ROBERT A. DRACKER

MD, MHA, MBA, CPI

Presentation: The Use of Intramuscular Ceftriaxone in Infants during the First Week of Life to Minimize the Risk of Late Onset Group B Strep Disease in Inadequately, Prenatally Treated Newborns

Dr. Dracker is the medical director of Summerwood Pediatrics in Syracuse, New York. Dr. Dracker is trained in Pediatrics, Pediatric Hematology/Oncology and Blood Banking/Transfusion Medicine. He has been in private practice since 1993 and along with his staff, cares for over 20,000 children in the Central New York Area. He is currently an advisor to the Pediatric Advisory Committee of the FDA and has been a previous board member and Chairman of the committee in 2019-2020.

ADRIENNE GORDON

MBChB, MRCP (UK), MPH (Hons), FRACP, PhD **Presentation:** IMproving Perinatal Mortality Review and Outcomes Via Education

Adrienne is a senior staff specialist Neonatologist in the RPA centre for newborn care and Clinical Professor in the Disciplines of Obstetrics, Gynaecology and Neonatology and Child and Adolescent Health, at Central and the Children's Hospital at Westmead Clinical Schools, within the Faculty of Medicine and Health at the University of Sydney. She trained in paediatrics prior to specialising in neonatal/perinatal medicine and is passionate about the public health impact of a healthy start to life and preventing adverse pregnancy outcome especially stillbirth. She is a Chief Investigator on the NHMRC Stillbirth Centre of Research Excellence, a Board Member of the Perinatal Society of Australia and New Zealand and on the executive commitee of the IMPACT Network (Improving Maternal and Perinatal Outcomes – Action through Clinical Trials). She has strong links with National parent led organisations - including Stillbirth and Preterm Birth Advocacy Groups both and is Deputy Chair of the National RedNose (Previously SIDSandKIDS) scientific advisory group. Adrienne currently leads the Public Awareness work within the Stillbirth Centre of Research Excellence which includes mass media campaign design and evaluation in collaboration with Prof Adrian Bauman from the University of Sydney. She is a key member of the Safer Baby Bundle initiative which aims to reduce late pregnancy stillbirth in Australia by 20% and a board member of the International Stillbirth Alliance. Adrienne is also National Coordinator of the IMPROVE program in Australia.



LISA HANSON

PhD, CNM, FACNM, FAAN **Presentation:** Two Clinical Trials: The Efficacy of Probiotics to Reduce Antenatal GBS

Dr. Lisa Hanson is Klein Endowed Professor of Women's Health Research at Marquette University College of Nursing and Associate Director of the Midwifery Program, Milwaukee WI, USA. She practiced as a Certified Nurse-Midwife for 29 years at the Aurora Midwifery and Wellness Center in Milwaukee, WI USA. For over a decade she has worked to develop the science to support the practice of using oral probiotic interventions to reduce antenatal GBS. She currently has two clinical trials in progress that she will discuss.



UDO HOYME

Univ.-Prof. Dr. med. habil. Prof. Dr. h.c.

Presentation: Successful prevention of early preterm birth by pH-measurement as a self-care habit in the State of Thuringia: Aspects of the 2020 experience

Udo Hoyme has served as Professor of Obstetrics and Gynecology practicing at the University of Tuebingen and at the University of Essen. He was chairman for almost 20 years at the Department of Obstetrics and Gynecology at the former Medical School in Erfurt until his "retirement" in 2013. In the following years he served as head of the OB/GYN Units in Eisenach and finally in Arnstadt. He is affiliated with the American IDSOG since 1979, and he has spent a research fellowship in urology at the UW Madison as well as a visiting professorship at the UW Seattle. His main topics include STI, bacterial vaginosis, prevention of preterm birth, and PID.



EMILY HUEBNER

MS

Presentation: The Impact of GBS Virulence Factors on Pregnancy and Neonatal Outcomes

Emily Huebner is a third-year medical student at the University of Washington and a member of the distinguished Adams Waldorf laboratory in the Department of Obstetrics and Gynecology. She began working on GBS research with the Adams Waldorf lab in her first year of medical school and was subsequently awarded a grant from the Infectious Diseases Society of America for her research. She hopes to continue to conduct research through her remaining medical school years and on into her medical career with the goal of improving pregnancy outcomes for those with GBS infections.



ELITA JAUNEIKAITE

BSc (Hons), PhD, MRSB

Presentation: Evolution of antimicrobial resistance in Group B streptococcus

Dr Elita Jauneikaite is an Advanced Research Fellow at Imperial College London, where she leads research on bacterial pathogenesis, global trends in vaccine-preventable infection and antibiotic resistance using bacterial genomics, bioinformatics and molecular biology techniques. Elita's research programme concentrates on investigating the global trends of disease-causing Group B Streptococcus (GBS) in humans and animals, with a focus on how GBS evolves over time, GBS transmission trends between different hosts and what are the antimicrobial resistance patterns present in disease and carriage GBS isolates. She is also a Research Lead for NIHR HPRU in HCAI and AMR Priority Pathogens theme, where Elita oversees genomics work on other bacterial pathogens including E. coli, K. pneumoniae, methicillin-susceptible S. aureus, S. argenteus and S. pyogenes.

RITWIJ KULKARNI

MSc, PhD

Presentation: Understanding the pathophysiology of GBS urinary tract infections in diabetes

Dr. Ritwij Kulkarni received his PhD from SUNY Stony Brook studying the importance of type II secretion and type IV pilus systems in uropathogenic *Escherichia coli*. Following this Dr. Kulkarni received postdoctoral training in the Department of Pediatrics at Columbia University studying host-pathogen interactions in the respiratory and urinary tracts. Dr. Kulkarni is working as assistant professor of immunology at University of Louisiana at Lafayette where his research group is focused on examining the effects of diabetic urinary microenvironment on the physiology of UTI caused by various Gram positive and Gram negative uropathogenic bacteria.

PHILIP KUM-NJI

MD, MPH

Presentation: Smoking as a risk factor for group B streptococcal colonization during pregnancy

Philip Kum-Nji: Born and educated in Cameroon where I obtained my MD but subsequently obtained an MPH from Tulane, New Orleans, LA. Afterwards did a residency in general pediatrics from the LeBonheur Children's Hospital, Memphis, TN. Was previously faculty at the University of Mississippi, Jackson, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA and now at the Children's Hospital Richmond, Richmond, VA. My research interest is mainly on the health effects of tobacco products (including e-cigarettes) on child health.



FATMA LEVENT

MD

Presentation: Long Term Outcomes of GBS Meningitis

Dr. Levent is currently the Medical Director of Pediatric Infectious Diseases at Advent Health for Children in Orlando, Florida. She also holds a Clinical Associate Professor appointment at Texas Tech Health Sciences Center in Lubbock, Texas. She is involved with patient care, quality & safety, resident and medical student education, infection prevention & control and antibiotic stewardship.



SUZY LIM

PhD Presentation: Breast Milk and Group B Streptococcus

Dr Suzy Lim is currently a post-doctoral researcher at St George's University of London, her work focuses on the development of assays to assess antibody functional and investigate the neonatal response to GBS infection. She earnt her Bachelors of Science in Microbiology at the University of Leicester in 2011 and her PhD in Infection and Immunity at the University of Liverpool in 2017. Her thesis assessed the efficacy of an immune modulating peptide in the treatment of bacterial sepsis. After completing her PhD, Suzanna went on to work on projects at the University of Liverpool focused on the development of novel antimicrobial therapies for Pseudomonas and Cryptococcus before joining the team at St George's in 2019.



EMILY MALLOY

CNM, APNP, PhD Candidate **Presentation:** The efficacy of an antenatal probiotic intervention to reduce residual group B streptococcus

Emily Malloy is a Certified Nurse Midwife in full-scope practice in a large midwifery practice in Wisconsin and a PhD Candidate working with Dr. Lisa Hanson at Marquette University. Her research interests include prenatal probiotics to reduce GBS colonization and residual GBS, which is the persistent cases of GBS disease despite universal screening, the microbiome, and waterbirth.



REBECCA E. MOORE

BS, MS

Presentation: Commensal *Streptococcus salivarius* overcomes suppression of growth by pathogenic Group B *Streptococcus*

Rebecca is a 4th year Ph.D candidate at Vanderbilt University in the Department of Chemistry. She is co-mentored by Dr. Steven Townsend and Dr. Jennifer Gaddy. She received her B.S. in Chemical Engineering from The University of Alabama and her M.S. in Chemistry from San Jose State University. She currently focuses on the antimicrobial and antibiofilm activities of human milk oligosaccharides against Group B Streptococcus.



BUHLE NTOZINI

BMedSci (Hons)

Presentation: Molecular characterization of invasive Group B streptococcus in South Africa, 2019-2020

Buhle Ntozini is a Masters student working on the molecular characterization of invasive Group B streptococcus at the National Institute for Communicable Diseases (NICD) in Johannesburg, South Africa.



KATHRYN A. PATRAS

PhD

Presentation: Impact of gestational diabetes on group B *Streptococcus* vaginal colonization and dissemination

Dr. Katy Patras is an Assistant Professor at Baylor College of Medicine. Her lab focuses on biological interactions between bacterial pathogens, mucosal immunity, and the microbiota of the female urogenital tract. Her research group seeks to develop new therapeutic applications to prevent bacterial infection as well as to increase our knowledge of the molecular mechanisms dictating overall women's health. This presentation focuses on the susceptibility of women with gestational diabetes to group B Streptococcus vaginal colonization and in utero complications.




MACY E. PELL

BS, PhD Candidate

Presentation: Investigating mechanisms of persistent Group B *Streptococcus* colonization after intrapartum antibiotic prophylaxis treatment

Macy Pell is a Ph.D. candidate in the lab of Dr. Shannon Manning at Michigan State University (MSU), currently studying pathogenesis mechanisms and genomic diversity of Group B Streptococcus (GBS). She is particularly interested in stress response and virulence mechanisms behind persistent infections of GBS during pregnancy. Macy received her Bachelor of Science degree from the University of Wisconsin-Madison in May of 2018 studying Microbiology. As an undergraduate, Macy investigated the population dynamics and diversity of Influenza viruses in non-human primate models in the lab of Dr. Thomas Friedrich. During the summers of her undergraduate career, Macy also performed research in Dr. Christopher Waters' lab at MSU where she studied second-messenger signaling pathways in Vibrio cholerae and co-authored her first publication. Macy's long-term research interests include understanding the virulence mechanisms of infectious microbes and the resulting impacts on human health. She plans to pursue a career in public health and infectious disease research to develop and improve upon disease prevention and awareness strategies.



KAREN M. PUOPOLO

Presentation: GBS Bacteriuria and Pregnancy

Karen M. Puopolo, M.D., Ph.D. is a neonatologist who specializes in neonatal infectious diseases. Dr. Puopolo is an Associate Professor of Pediatrics on the faculty of the University of Pennsylvania Perelman School of Medicine. She is a member of the Division of Neonatology at The Children's Hospital of Philadelphia, and Section Chief for Newborn Medicine at Pennsylvania Hospital. Dr. Puopolo received her undergraduate degree in physics from Yale University, and went on to obtain her M.D. as well as a Ph.D. in molecular physiology from the Tufts University School of Medicine in Boston. She completed Pediatric residency and Neonatal-Perinatal fellowship training at Boston Children's Hospital. Dr. Puopolo was appointed to the faculty of Harvard Medical School from 2000-2014 where she was a physician and researcher at the Brigham and Women's Hospital and the Channing Laboratory investigating mechanisms of virulence in Group B Streptococcus. Her current research focuses on neonatal sepsis epidemiology and risk assessment. She is currently funded by the National Institutes of Health and the CDC to study the impact of neonatal antibiotic exposures on the newborn and early childhood microbiome, and on infant and early childhood growth. Dr. Puopolo is a member of the American Academy of Pediatrics Committee on the Fetus and Newborn and serves on the Editorial Board for *Pediatrics*.



BRADY L. SPENCER

PhD

Presentation: A type VII secretion system in Group B *Streptococcus* mediates cytotoxicity and virulence

Dr. Brady Spencer received her PhD in Microbiology from the University of Alabama at Birmingham in 2017 and joined the lab of Kelly Doran for her postdoctoral studies at the University of Colorado Denver. She is interested in pathogenesis of Group B Streptococcus, particularly how secreted proteins influence pathogenesis and modulate host immune responses.



SABRINA K. SPICER

BS, current PhD student

Presentation: Antibiotic adjuvants: rejuvenating our current arsenal of antimicrobials against Group B *Streptococcus*

Born and raised in Nashville, Tennessee, Sabrina completed her B.S. in Biochemistry at Middle Tennessee State University in 2019. As an undergraduate she investigated the utility of antimicrobial peptides against invasive fungal infections. After a brief period of working as a clinical research intern under the direction of Dr. Samuel Hunter (MD, Ph.D.) she decided to pursue her own Ph.D at Vanderbilt University with Dr. Steven Townsend and Dr. Jennifer Gaddy. In her free time, she enjoys hiking with her two dogs.

HOLOGIC

Power in **Sensitivity**

In a clinical trial, the Panther Fusion® GBS assay demonstrated **100% sensitivity** and **96.5% specificity** when compared to culture-based testing methods.¹

When screening for Group B streptococcus, molecular is the optimal choice when compared to culture-based screening.²

The Panther Fusion GBS assay provides excellent, accurate results expectant mothers and their providers can rely on.¹





Proud Supporter of GBS Awareness Month



References: 1. Panther Fusion GBS assay [US package insert]. AW-17997. San Diego, CA: Hologic, Inc., 2018. 2. Shin JH and Pride DT. Comparison of Three Nucleic Acid Amplification Tests (NAATs) and Culture for Detection of Group B Streptococcus (GBS) from Enrichment Broth. J Clin Microbiol; 2019; JCM.01958-18. doi:10.1128/JCM.01958-18 ADS-02670-001 Rev. 002 © 2020 Hologic, Inc. All rights reserved. Hologic, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries

THANK YOU TO OUR EMERALD SPONSOR

